Xeris Biopharma Holdings, Inc.
XERSNasdaq
$8.80
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↑ +67.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.6B
Enterprise Value
$1.7B
P/E
125.7
P/S
5.0
P/B
120.1
EV/EBITDA
44.9
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$314.9M
Net Income (TTM)
$12.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
11.4%
Net Margin
3.8%
ROE
92.3%
ROIC
23.2%
Debt / Equity
17.0
Net Cash
-$109.5M
Return 1Y
+68.3%
Company profile
Xeris Biopharma Holdings, Inc. engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the. treatment of hyperkalemic, hypokalemic. and related variants of primary periodic paralysis.
- CEO
- Paul R. Edick
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 290
- Headquarters
- Illinois
- Website
- xerispharma.com
Management & directors
- Pieper StevenSee Remarks
- Hecht BethSee Remarks
- Mcculloch KevinSee Remarks
- Nguyen Anh TuSee Remarks
- Shannon John Patrick JrSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
XERS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$83.1M↑ +38.3%
Diluted EPS$0.01↓ -116.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.4M | $49.6M | $110.2M | $163.9M | $203.1M | $291.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$83.5M | -$115.2M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Net income | -$91.1M | -$122.7M | -$94.7M | -$62.3M | -$54.8M | $554,000.00 |
| Diluted EPS | — | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Operating cash flow | -$80.6M | -$95.5M | -$102.9M | -$47.0M | -$37.0M | $28.6M |
| Free cash flow | -$80.9M | -$96.6M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -408.8% | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Net margin | -446.0% | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $54.3M | $60.1M | $60.1M | $71.5M | $74.4M | $85.8M | $83.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.2M | -$12.9M | $1.7M | -$3.1M | $4.5M | $6.7M | $16.8M | $7.9M |
| Net income | -$15.0M | -$15.7M | -$5.1M | -$9.2M | -$1.9M | $621,000.00 | $11.1M | $2.2M |
| Diluted EPS | -$0.10 | -$0.11 | -$0.02 | -$0.06 | -$0.01 | $0.00 | $0.07 | $0.01 |
| Operating cash flow | -$10.3M | -$8.3M | $2.0M | -$10.0M | $182,000.00 | $18.4M | $20.0M | $9.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -17.0% | -23.8% | 2.8% | -5.1% | 6.3% | 9.0% | 19.5% | 9.5% |
| Net margin | -31.2% | -29.0% | -8.5% | -15.3% | -2.7% | 0.8% | 12.9% | 2.7% |
Company news
Jul 8, 2026
Jun 30, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Pieper Steven· See Remarks | Sale | 27,600 | $8.52 | $235,276.20 | filing |
| 2026-07-06 | Pieper Steven· See Remarks | Sale | 17,400 | $8.50 | $147,900.00 | filing |
| 2026-07-01 | McCulloch Kevin· See Remarks | Sale | 90,000 | $8.03 | $722,511.00 | filing |
| 2026-07-01 | Hecht Beth· See Remarks | Sale | 16,666 | $8.03 | $133,859.65 | filing |
| 2026-07-01 | KREHER NERISSA | Award | 33,582 | $0.00 | $0.00 | filing |
| 2026-06-04 | HALKUFF DAWN | Sale | 20,000 | $6.09 | $121,886.00 | filing |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Sale | 16,000 | $6.09 | $97,507.20 | filing |
| 2026-06-04 | JOHNSON JOHN | Sale | 15,000 | $6.09 | $91,422.00 | filing |
| 2026-06-04 | Brady James Aloysius | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-04 | Kong Garheng | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-04 | PERSKY MARLA | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-04 | HALKUFF DAWN | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-04 | JOHNSON JOHN | Award | 24,193 | $0.00 | $0.00 | filing |
| 2026-06-03 | PERSKY MARLA | Sale | 15,500 | $5.90 | $91,432.95 | filing |
| 2026-06-01 | Hecht Beth· See Remarks | Sale | 16,667 | $6.06 | $100,982.02 | filing |
| 2026-05-01 | Hecht Beth· See Remarks | Sale | 16,667 | $6.23 | $103,805.41 | filing |
| 2026-04-01 | Hecht Beth· See Remarks | Sale | 16,667 | $5.99 | $99,858.66 | filing |
| 2026-03-30 | Brady James Aloysius | Sale | 10,834 | $5.54 | $60,035.53 | filing |
| 2026-03-12 | McCulloch Kevin· See Remarks | Option exercise | 48,894 | $4.09 | $199,976.46 | filing |
| 2026-03-12 | McCulloch Kevin· See Remarks | Option exercise | 4 | $3.94 | $15.76 | filing |
| 2026-03-05 | Pieper Steven· See Remarks | Option exercise | 27,891 | $4.09 | $114,074.19 | filing |
| 2026-03-05 | Pieper Steven· See Remarks | Option exercise | 14,036 | $5.93 | $83,233.48 | filing |
| 2026-03-02 | Hecht Beth· See Remarks | Sale | 16,567 | $6.24 | $103,379.74 | filing |
| 2026-03-02 | Hecht Beth· See Remarks | Sale | 100 | $7.06 | $706.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.